Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19

Pharmacol Res. 2021 Feb:164:105402. doi: 10.1016/j.phrs.2020.105402. Epub 2020 Dec 24.

Authors

Emilio Di Maria¹, Paolo Martini², Massimo Gennarelli³

Affiliations

¹ Dept. of Health Sciences, University of Genoa, Italy; Unit of Medical Genetics, Galliera Hospital, Genoa, Italy. Electronic address: emilio.dimaria@unige.it.
² Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
³ Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

COVID-19*
Flavanones
Genomics
Humans
Pharmaceutical Preparations*
SARS-CoV-2

Substances

Flavanones
Pharmaceutical Preparations
naringenin